SBC Medical Group announces U.S. market entry as Emerging Growth Research maintains Buy-Extended rating and $9.00 target

Emerging Growth Research kept a Buy-Extended rating and a $9.00 12-month price target on SBC Medical Group after the company made a minority investment and collaboration with U.S. MedSpa chain OrangeTwist.

SBC Medical Group has entered the U.S. medical aesthetics market through a minority equity investment and a structured collaboration with OrangeTwist, a U.S. MedSpa chain. The article mentions Emerging Growth Research released a Flash Report that maintained a Buy-Extended rating and a 12-month price target of $9.00. The report recalls SBC's growth from a single clinic founded in 2000 to a franchiser with operations in Japan and several Asian markets. The OrangeTwist transaction is presented as part of SBC's longer-term plan to expand its clinic network. Key details: - The article mentions Emerging Growth Research maintained a Buy-Extended rating and a $9.00 12-month price target, and cited SBC's closing price of $4.44 on January 6, 2026. - SBC completed a minority equity investment and structured collaboration with OrangeTwist to establish a presence in the United States. - OrangeTwist is described as operating 24 locations across six U.S. states and offering non-invasive aesthetic treatments with medical oversight and data-driven operations. - The Flash Report states SBC currently operates 258 clinics and has a stated long-term target to reach 1,000 clinics over ten years via domestic growth and strategic M&A. - The report characterizes SBC as having about 25 years of operational history and ongoing cash generation, according to the analyst's analysis. Summary: The Flash Report frames the OrangeTwist investment as a strategic milestone for SBC's international growth and notes the analyst's expectation of revenue growth resuming in 2026. The report and the company include forward-looking statements about clinic expansion, M&A strategy, and operational synergies, and the press release acknowledges those statements are subject to risks and uncertainties. Next steps described in the release focus on pursuing the planned clinic expansion and executing the collaboration with OrangeTwist as part of SBC's broader international strategy.